LEXINGTON, Mass.—Today Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, has announced the closing of a $65 million Series B financing. The proceeds will be used to advance lead programs from the company’s growing pipeline into clinical testing, including small molecule monoPARP inhibitors.
The financing was led by the Novartis Venture Fund. Novartis was also joined by new investors JJDC and Celgene Corporation, as well as existing investors, The Column Group, Deerfield Management, U.S. Venture Partners, Osage University Partners, Takeda Ventures and Euclidean Capital.
“We are delighted to have the support of such a distinguished group of investors who share our commitment to bringing novel therapies to cancer patients and excitement for the therapeutic potential of modulating cellular stress responses,” said Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “Leveraging landmark discoveries made by our scientific founders, which ushered in a better understanding of the molecular action and biological function of novel enzyme classes beginning with monoPARPs, we are applying our expertise in drug discovery to develop novel and effective treatments for defined patient populations with limited therapeutic options.”
MonoPARPs are key regulators of stress responses that enable cancer cells to survive and also evade immune detection, and emerging science has linked their activity with disease development. Ribon has built an integrated technology platform to investigate monoPARPs, in order to develop first-in-class, small molecule therapeutics. The company initially plans to focus in oncology; however, the 12 distinct monoPARPs function across a variety of stress responses relevant to disease development in cancer, inflammatory diseases and neurodegenerative diseases. This gives Ribon’s approach broad utility. The focus of Ribon’s lead program is on advancing the science of PARP7 inhibitors for the treatment of cancer, beginning with squamous cell carcinoma of the lung.
“We have been following Victoria and her team for more than a year and are impressed by Ribon’s tremendous progress and ability to execute,” noted Anja Koenig, Head of the Novartis Venture Fund, who will be joining the Ribon board of directors as part of the Series B financing along with an investor from JJDC. “Ribon has developed a novel platform with the flexibility and rigor to investigate and exploit new targets, providing the opportunity to build a diverse and attractive pipeline of first-in-class therapeutics.”